Figure 6.

Increased MYB is associated with suppressed immune activation. (A) CD8⁺ TILs were isolated from tumors generated by parental and MYB-GFP-CT26 cells and assessed for activation marker CD44. (B) Tumor draining lymph nodes were isolated on the basis of CD4⁺ or CD8⁺ expression and then evaluated for T-cell activation markers CD62L and CD44. Significantly reduced activation status was observed in mice bearing MYB-GFP-CT26 tumors; (*p < 0.05, t-test). (C) Tumor growth was indistinguishable when CT26 cells with either MYB-GFP or GFP were compared following doses of isotype control antibodies (200 mg IP) at day 5, 10 and 15 post tumor cell inoculation (arrows). (D) When mice bearing CT26 MYB-GFP cells were treated with anti-PD-1 antibodies (200 mg IP) at day 5, 10 and 15 (arrows) 3/6 mice escaped growth inhibition compared to 0/6 mice in the CT26-GFP control group.